Price
$4.01
Decreased by -2.67%
Dollar Volume
4.59 M
ADR%
6.52
Earnings Report Date (estimate)
Mar 7, 23 (0.13)
Market Cap.
193.66 M
Shares Float
47.61 M
Shares Outstanding
48.29 M
Beta
1.51
Price / Earnings
7.29
BPR
323.39
20D Range
3.50 4.44
50D Range
2.75 4.44
200D Range
1.86 4.44
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 0.08
Increased by 0.00%
0.07
Increased by +14.29%
Aug 8, 22 0.16
Increased by +150.00%
0.08
Increased by +100.00%
May 9, 22 0.20
Increased by +25.00%
0.09
Increased by +122.22%
Mar 9, 22 0.10
Increased by +433.33%
0.12
Decreased by -16.67%
Nov 4, 21 0.08
Increased by +166.67%
-0.04
Increased by +300.00%
Aug 5, 21 -0.32
Decreased by -420.00%
0.12
Decreased by -366.67%
May 6, 21 0.16
Increased by +214.29%
0.02
Increased by +700.00%
Nov 6, 20 -0.03
Decreased by -112.50%
0.01
Decreased by -400.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 34.21 M
Increased by +34.31%
4.17 M
Increased by +11.69%
Increased by +12.20%
Decreased by -16.84%
Jun 30, 22 35.13 M
Increased by +38.46%
7.83 M
Increased by +155.29%
Increased by +22.30%
Increased by +139.93%
Mar 31, 22 36.54 M
Increased by +36.14%
9.06 M
Increased by +99.47%
Increased by +24.81%
Increased by +46.52%
Dec 31, 21 33.33 M
Increased by +10.45%
4.61 M
Increased by +118.91%
Increased by +13.82%
Increased by +117.12%
Sep 30, 21 25.47 M
Decreased by -26.31%
3.74 M
Increased by +135.52%
Increased by +14.67%
Increased by +148.19%
Jun 30, 21 25.37 M
Increased by +23.07%
-14.17 M
Increased by +58.93%
Decreased by -55.84%
Increased by +66.63%
Mar 31, 21 26.84 M
Increased by +28.31%
4.54 M
Decreased by -88.98%
Increased by +16.93%
Decreased by -91.41%
Dec 31, 20 30.18 M
Decreased by -49.05%
-24.35 M
Increased by +87.36%
Decreased by -80.70%
Increased by +75.19%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.